Literature DB >> 20570171

Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature.

K Kamposioras1, G Pentheroudakis, D Pectasides, N Pavlidis.   

Abstract

INTRODUCTION: Although more than 90% of melanomas have a cutaneous origin, occasionally it is discovered as a secondary deposit without evident primary site. The aim of this study was to systematically review published literature and analyse data on incidence, presentation, therapeutic interventions, survival and prognostic factors.
METHODS: We searched MEDLINE, (search terms Melanom*, unknown origin, unknown primary, indolent, occult) and the abstracts from major congresses of the last 4 years and perused the references of the retrieved relevant articles.
RESULTS: 4348 patients with MUP were reported along with 132,643 patients with Melanoma of Known Primary (MKP). The incidence of MUP was 3.2%. The male to female ratio was 2:1 while the age peak was in the 4th and 5th decades. MUP patients harbouring nodal disease had a median overall survival ranging between 24 and 127 months, 5-year survival rate between 28.6% and 75.6% and 10-year survival rate between 18.8% and 62.9%. MUP patients with visceral disease had median survival times between 3 and 16 months, and 5-year survival rates between 5.9% and 18%. Presence of tumour regression in metastatic sites and low nodal burden were associated with favourable outcome. Potentially curative surgical treatment offered survival advantage in comparison to patients with residual metastatic foci. MUP patients who received adjuvant chemotherapy or radiotherapy paradoxically seemed to fare worse compared to patients observed.
CONCLUSIONS: This is the first review to bring together the information of 89 years and to analyze all the potential information accumulated. Although a well know entity no consensus is reached in order to describe MUP presentation, management or prognosis. 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20570171     DOI: 10.1016/j.critrevonc.2010.04.007

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  40 in total

1.  Vitiligo-like hypopigmentation and metastatic melanoma of unknown primary site: friends or foes?

Authors:  Julio Cesar Salas-Alanis; Roger Gonzalez; Giulio Fortuna
Journal:  Med Oncol       Date:  2012-12       Impact factor: 3.064

2.  Primary Pulmonary Malignant Melanoma: An Unexpected Tumor.

Authors:  Kyo-Bum Hwang; Ki-Eun Hwang; Jae-Wan Jung; Su-Jin Oh; Mi-Jeong Park; Young-Hoon Jeong; Keum-Ha Choi; Eun-Taik Jeong; Hak-Ryul Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2015-06-30

Review 3.  Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.

Authors:  Teresa C Longoria; Krishnansu S Tewari
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-08-16       Impact factor: 4.481

4.  Primary biliary tract melanoma: Report of a case and review of the literature.

Authors:  Nathaniel E Smith; Janis M Taube; Tam M Warczynski; Kevin D Collier; Timothy M Pawlik
Journal:  Int J Surg Case Rep       Date:  2012-05-24

5.  Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling.

Authors:  James P De Andrade; Paul Wong; Michael P O'Leary; Vishwas Parekh; Arya Amini; Hans F Schoellhammer; Kim A Margolin; Michelle Afkhami; Laleh G Melstrom
Journal:  Ann Surg Oncol       Date:  2020-09-09       Impact factor: 5.344

6.  Insights into the Role of PAX-3 in the Development of Melanocytes and Melanoma.

Authors:  Jessica Diann Hathaway; Azizul Haque
Journal:  Open Cancer J       Date:  2011-01-01

Review 7.  [Ways to personalized medicine for gastric cancer].

Authors:  C Röcken
Journal:  Pathologe       Date:  2013-09       Impact factor: 1.011

8.  Melanoma with unknown primary: report and analysis of 24 patients.

Authors:  Rita Clerico; Ugo Bottoni; Giovanni Paolino; Marina Ambrifi; Paola Corsetti; Valeria Devirgiliis; Stefano Calvieri
Journal:  Med Oncol       Date:  2012-03-30       Impact factor: 3.064

9.  Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.

Authors:  Janis M Taube; Robert A Anders; Geoffrey D Young; Haiying Xu; Rajni Sharma; Tracee L McMiller; Shuming Chen; Alison P Klein; Drew M Pardoll; Suzanne L Topalian; Lieping Chen
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

Review 10.  Survival is not the only valuable end point in melanoma screening.

Authors:  Clara Curiel-Lewandrowski; Caroline C Kim; Susan M Swetter; Suephy C Chen; Allan C Halpern; John M Kirkwood; Sancy A Leachman; Ashfaq A Marghoob; Michael E Ming; James M Grichnik
Journal:  J Invest Dermatol       Date:  2012-02-16       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.